CVS wants payback from GMP violators; Genzyme sued for Fabrazyme rationing;

> CVS Pharmacy is demanding $100 million from KV Pharmaceutical, Ethex and Nesher Pharmaceuticals for halting the supply of generics in 2008 due to GMP failures. News

> Fabry disease sufferers have filed suit against Genzyme and Mt. Sinai Medical School, the developer and license holder of Fabrazyme, for their handling of the drug shortage. Story

> Regional drug-production hubs created via big pharma tech transfer can improve public health and drive economic development in low- to mid-income countries, says Eli Lilly. Article

> Sanofi has recalled nearly 200,000 doses of the ActHIB flu vaccine in Japan; users found foreign matter in the syringes after injection. Story

> Amgen will buy a Pfizer manufacturing plant at Dun Laoghaire, County Dublin, securing 280 jobs. Release

> In response to a new healthcare reform reimbursement policy, doctors are balking at writing prescriptions for OTC products and pharmacists are complaining about filling them. Item

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.